Synthesis of harmine-nitric oxide donor derivatives as potential antitumor agents

被引：7

作者：

Li, Zhezhe ^{[1
]}

Apizi, Yipaerguli ^{[1
]}

Zhang, Chengzhong ^{[4
]}

Wang, Zhaozhi ^{[1
]}

He, Hongji ^{[1
]}

Li, Xiaoya ^{[2
]}

Zhu, Yina ^{[2
]}

Yang, Jishun ^{[3
]}

Xiao, Liang ^{[2
]}

Wang, Mei ^{[1
]}

机构：

[1] Xinjiang Med Univ, Coll Pharm, Urumqi 830000, Peoples R China

[2] Naval Med Univ, Mil Med Univ 2, Fac Naval Med, Shanghai 200433, Peoples R China

[3] Naval Med Univ, Mil Med Univ 2, Characterist Med Ctr, Shanghai 200052, Peoples R China

[4] Naval Med Univ, Mil Med Univ 2, Dept Pharm, Shanghai 200433, Peoples R China

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2022年 / 65卷

基金：

中国国家自然科学基金;

关键词：

Harmine; Antitumor; NO releasing; Apoptosis; Derivative; Synthesis;

D O I：

10.1016/j.bmcl.2022.128698

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

To further improve the anti-tumor activity of Harmine (HM), we took the hybridization approach and synthesized harmine derivatives-furoxan hybrids containing nitric oxide (NO) releasing parts by connecting NO donors with anti-tumor active fragments to harmine. Then, the synthesized compounds were evaluated for their in vitro cytotoxicity against five human cancer cell lines. Among them, compound 10 was found to have the strongest antiproliferative activity against HepG2 (IC50 = 1.79 mu M). In addition, compound 10 produced high levels of NO in vitro, verifying that the release of NO was closely correlated to the antiproliferative activity. In addition, Compound 10 also showed good plasma stability. Finally, we also preliminarily investigated the acute toxicity of compound 10 in mice and assessed the absorption of compound 10 by Caco-2 cell permeability assay. In brief, the remarkable biological characteristics of the new harmine derivatives-furoxan hybrids may make them promising candidates for human cancer intervention.

引用

页数：7

共 32 条

[1] Identification of harman as the antibiotic compound produced by a tunicate-associated bacterium [J].

Aassila, H ;

Bourguet-Kondracki, ML ;

Rifai, S ;

Fassouane, A ;

Guyot, M .

MARINE BIOTECHNOLOGY, 2003, 5 (02) :163-166

[2]

Atefeh J, 2021, CURR PHARM DESIGN, V27, P185

[3] Novel Structural Hybrids on the Base of Benzofuroxans and Furoxans. Mini-Review [J].

Chugunova, Elena A. ;

Burilov, Alexander R. .

CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2017, 17 (09) :986-1005

[4]

CHUNMING M, 2010, EUR J MED CHEM, V45, P1515

[5] NO donors: Focus on furoxan derivatives [J].

Gasco, A ;

Fruttero, R ;

Sorba, G ;

Di Stilo, A ;

Calvino, R .

PURE AND APPLIED CHEMISTRY, 2004, 76 (05) :973-981

[6]

HONGTAO D, 2016, BIOORG MED CHEM LETT, V26, P4015

[7]

IoannaChrysoula T, 2021, INT J MOL SCI, V22

[8] Dual Intratumoral Redox/Enzyme-Responsive NO-Releasing Nanomedicine for the Specific, High-Efficacy, and Low-Toxic Cancer Therapy [J].

Jia, Xiaobo ;

Zhang, Yihua ;

Zou, Yu ;

Wang, Yao ;

Niu, Dechao ;

He, Qianjun ;

Huang, Zhangjian ;

Zhu, Weihong ;

Tian, He ;

Shi, Jianlin ;

Li, Yongsheng .

ADVANCED MATERIALS, 2018, 30 (30)

[9]

Junjie F, 2019, J MED CHEM, V62, P10473

[10] Recent pharmacological developments in β-carboline alkaloid "harmaline" [J].

Khan, Farhan A. ;

Maalik, Aneela ;

Iqbal, Zafar ;

Malik, Imran .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 721 (1-3) :391-394

← 1 2 3 4 →